The page you are about to visit is not owned or operated by Forma. Forma is not responsible for your use of the site, nor does it control, endorse, or guarantee any aspect of your experience there. Please read the site’s Terms of Use and Privacy Policy and confirm you are comfortable with those terms, which may differ from Forma’s, before using the site.
CONTINUEHelp us be even better by letting us know what we're missing. We appreciate you're calling it out.
SUBMITDon't miss this chance to stay up to date on the latest in sickle cell transition information and resources.
I may opt out at any time by clicking the “unsubscribe” link within any email I receive, by calling 1-877-744-2579, or by sending a letter containing my name, address(es), and email address(es) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy and what other information may be collected from you while you use this service, please see our Privacy Notice. GET ME LOOPED IN
Total funding committed by Forma Therapeutics, a Novo Nordisk company, has exceeded $1.5M with several grants awarded that span multiple years.
The recipient organizations include patient and community groups, healthcare institutions, and professional associations. These cover a range of local, regional, and national organizations serving SCD communities in different states across the US.
All grants selected for funding have measurable outcomes and quality metrics that will be reported and published, as appropriate.
ASH Research Collaborative (ASH RC)
Program:
A Nationwide Learning Community to Improve Transitions of SCD Care
Unique Purpose:
Leverage the ASH RC SCD Learning Community and Data Hub to improve transition from pediatric to adult care by developing measures and evidence-informed quality improvement tools, to support patient preparedness and healthcare system support for transition, which will be implemented and assessed at sites in the ASH RC SCD Learning Community.
Emory University School of Medicine, Department of Pediatrics
Maryland Sickle Cell Disease Association (MSCDA)
National Alliance of Sickle Cell Centers (NASCC)
Next Step Fund
The Ohio State University Wexner Medical Center
Piedmont Health Services and Sickle Cell Agency
Transition TBH is a series of videos where SCD patients, doctors and social workers share their stories and tips for transition. We’ve handpicked our guests to make sure that you get something valuable out of this series.
Dr. Nirmish Shah, the Director of the SCD Transition Program at Duke University, talks about the importance of transition and shares his expert tips to ace it.
